MedPath

A prospective clinical phase II study of allogeneic stem cell transplantation using conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for patients with acute lymphoblastic leukemia.

Phase 2
Completed
Conditions
Acute lymphoblastic leukeimia Acute biphenotypic leukemia (Acute leukemias of ambiguous lineage )
Registration Number
JPRN-UMIN000001672
Lead Sponsor
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1.ALL L3 (Burkitt leukemia) 2. Positivity for HBs antigen and/or HCV antibody and/or HIV antibody 3. Double cancers 4. Infection that need to be treated 5. Severe mental disorder 6. Pregnant or breast-feeding woman 7. Uncontrolled diabetes mellitus even by insulin treatment 8. Myocardial infarction or heart failure 9. Liver cirrhosis 10. Body mass index more than 35 11. Severe arrhythmia 12. Having pentostatin 13. Severe allergy for VP-16 or cyclophosphamide 14.An inappropriate patient judged by the medical attendant

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath